On April 28, 2025 AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, reported an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 25-30, 2025 at McCormick Place Convention Center in Chicago, IL (Press release, AffyImmune Therapeutics, APR 28, 2025, View Source [SID1234652276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting our updated Phase 1 data at AACR (Free AACR Whitepaper), and to provide interim safety and efficacy results from our Phase 1 Dose Escalation trial evaluating AIC100 CAR T therapy in patients with advanced thyroid cancers," said Daniel Janse, CEO, AffyImmune. "These results mark progress, as we plan the next steps for our affinity-tuned CAR T therapies for patients with unmet medical need."

Presentation Details:

Title: ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with Advanced Thyroid cancers: Clinical and translational data from the phase 1 dose escalation study

Presenter: Dr. Samer Ali Srour, University of Texas MD Anderson Cancer Center, Houston, TX

Session Type: Oral Presentation – Clinical Trials Plenary Session

Abstract Number: CT206

Date and Time: April 29, 2025 10:15AM – 12:15PM CST

Location: McCormick Place Convention Center in Chicago, Illinois